| scholarly article | Q13442814 |
| P356 | DOI | 10.1681/ASN.2005090955 |
| P698 | PubMed publication ID | 16481415 |
| P50 | author | Wolfgang Winkelmayer | Q89531312 |
| P2093 | author name string | Christa Mitterbauer | |
| Rainer Oberbauer | |||
| Gary C Curhan | |||
| Reinhard Kramar | |||
| Georg Heinze | |||
| Heinz Regele | |||
| P433 | issue | 3 | |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 889-899 | |
| P577 | publication date | 2006-02-15 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation | |
| P478 | volume | 17 |
| Q92054729 | A retrospective study of the relationship between postoperative urine output and one year transplanted kidney function |
| Q81524393 | ACE inhibition after renal transplantation: the effect on persistent left ventricular hypertrophy |
| Q36285590 | Albuminuria-reducing effect of angiotensin II receptor blocker plus hydrochlorothiazide combination therapy in renal transplant recipients |
| Q46187856 | Anemia after renal transplantation: an underestimated problem |
| Q44542363 | Anemia is associated with mortality in kidney-transplanted patients--a prospective cohort study. |
| Q36574775 | Angiotensin II blockade in kidney transplant recipients |
| Q46613237 | Angiotensin-converting enzyme inhibitors after renal transplantation |
| Q33871267 | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain |
| Q36906370 | Antihypertensive pharmacotherapy and long-term outcomes in pediatric kidney transplantation |
| Q37293235 | Are the current chronic allograft nephropathy grading systems sufficient to predict renal allograft survival? |
| Q35658644 | Assessment and management of hypertension in transplant patients |
| Q42712430 | BP targets in renal transplant recipients: too high or too low? |
| Q36701855 | Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients |
| Q38223778 | Biological pathways and potential targets for prevention and therapy of chronic allograft nephropathy |
| Q39968149 | Cardiac Events After Kidney Transplantation According to Pretransplantation Coronary Artery Disease and Coronary Revascularization Status |
| Q90595680 | Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Renal Transplant Recipients |
| Q38177489 | Cardiovascular complications after transplantation: treatment options in solid organ recipients |
| Q26771406 | Cardiovascular risk factors following renal transplant |
| Q87393480 | Chapter 5: Blood pressure management in kidney transplant recipients (CKD T) |
| Q53320581 | DNA double-strand breaks induced intractable glomerular fibrosis in renal allografts. |
| Q34224452 | Diagnosis and prevention of chronic kidney allograft loss |
| Q40452726 | Dialysis Vintage and Outcomes after Kidney Transplantation: A Retrospective Cohort Study. |
| Q37779518 | Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease? |
| Q46059118 | Does posttransplant anemia at 6 months affect long-term outcome of live-donor kidney transplantation? A single-center experience |
| Q39626782 | Early inhibition of the renin-angiotensin system improves the long-term graft survival of single pediatric donor kidneys transplanted in adult recipients |
| Q53425824 | Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus. |
| Q40704900 | Effect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study |
| Q64263285 | Effects of Telmisartan and Candesartan on the Metabolism of Lipids and Glucose in Kidney Transplant Patients: A Prospective, Randomized Crossover Study |
| Q37638064 | Fibrogenesis in kidney transplantation: potential targets for prevention and therapy |
| Q46105873 | Fluctuations of exercise capacity in patients after kidney transplantation |
| Q36689228 | Gene expression and biomarkers in renal transplant ischemia reperfusion injury. |
| Q33813163 | HNF4alpha dysfunction as a molecular rational for cyclosporine induced hypertension |
| Q35985207 | Hemoglobin variability after renal transplantation is associated with mortality |
| Q37964270 | Histology and proteinuria after renal transplantation |
| Q88920000 | Hyperfiltration-mediated Injury in the Remaining Kidney of a Transplant Donor |
| Q38128162 | Hypertension after kidney transplantation: a pathophysiologic approach |
| Q36873134 | Hypertension after renal transplant |
| Q81484667 | Hypertension after renal transplantation |
| Q57190615 | Hypertension guidelines: How do they apply to kidney transplant recipients |
| Q37253882 | Hypertension in dialysis and kidney transplant patients |
| Q37764468 | Hypertension in the kidney transplant recipient. |
| Q58992876 | Hypertension: The Neglected Complication of Transplantation |
| Q36736723 | Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection |
| Q37953963 | Impact of post-transplant anemia on patient and graft survival rates after kidney transplantation: a meta-analysis |
| Q62825186 | Increasing Levels of Hemoglobin Improve Renal Transplantation Outcomes |
| Q37822152 | Individualizing early use of sirolimus in renal transplantation |
| Q90595687 | Influence of Renin-Angiotensin System Blockers on Graft Function in Retrospective Analysis of Pairs of Renal Transplant Recipients From the Same Donor |
| Q42943601 | Insertion/Deletion polymorphism of Angiotensin-converting enzyme as a risk factor for chronic allograft nephropathy |
| Q91665599 | Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation |
| Q37051488 | Is RAS blockade routinely indicated in hypertensive kidney transplant patients? |
| Q38605687 | Keys to long-term care of the liver transplant recipient |
| Q39035802 | Kidney Fibrosis: Origins and Interventions |
| Q35153318 | Late kidney allograft loss: what we know about it, and what we can do about it |
| Q37359082 | Left atrial diameter and survival among renal allograft recipients |
| Q64269252 | Management of Hypertension in Chronic Kidney Disease |
| Q90595693 | Management of Renin-Angiotensin-Aldosterone System Blockade in Kidney Transplant Recipients |
| Q37089454 | Management of cardiovascular disease in renal transplant recipients |
| Q37964274 | Management of proteinuria in clinical practice after kidney transplantation. |
| Q37149434 | Mechanisms and management of proteinuria in kidney transplant patients |
| Q37853831 | Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. |
| Q37078089 | Minimal proteinuria one year after transplant is a risk factor for graft survival in kidney transplantation |
| Q87214989 | Modulating kidney transplant interstitial fibrosis and tubular atrophy: is the RAAS an important target? |
| Q37072784 | Nanoparticle PET-CT detects rejection and immunomodulation in cardiac allografts |
| Q37813417 | Non-immune interventions to protect kidney allografts in the long term |
| Q64242337 | Post renal transplant anemia: severity, causes and their association with graft and patient survival |
| Q38657521 | Post-transplantation diabetes-state of the art. |
| Q41390396 | Posttransplantation anemia in kidney transplant recipients: A retrospective cohort study |
| Q46894265 | Posttransplantation glomerulonephritis: risk factors associated with kidney allograft loss. |
| Q38544101 | Potential New Agents for the Management of Hyperkalemia |
| Q37945873 | Prevention of cardiovascular disease in adult recipients of kidney transplants |
| Q38012182 | Proteinuria after kidney transplantation |
| Q41096391 | Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial |
| Q93609101 | References |
| Q52845695 | Renal Association Clinical Practice Guideline on post-operative care of the kidney transplant recipient. |
| Q38359455 | Renal allograft fibrosis: biology and therapeutic targets |
| Q58868704 | Renin–angiotensin system blockade and kidney transplantation: a longitudinal cohort study |
| Q53096709 | Short- and long-term effects of the use of RAAS blockers immediately after renal transplantation. |
| Q36276748 | Short- and long-term outcomes with renin-angiotensin-aldosterone inhibitors in renal transplant recipients: A meta-analysis of randomized controlled trials |
| Q89724870 | Should ACE inhibitors or calcium channel blockers be used for post-transplant hypertension? |
| Q48904824 | Specific management of anemia and hypertension in renal transplant recipients: influence of renin-angiotensin system blockade |
| Q36246782 | Steroid withdrawal after renal transplantation: a retrospective cohort study. |
| Q39340117 | Strategies for long-term preservation of kidney graft function |
| Q46045283 | Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy |
| Q38825505 | The Effect of Renin-angiotensin System Inhibitors on Kidney Allograft Survival: A Systematic Review and Meta-analysis |
| Q38051422 | The nephroprotective properties of recombinant human erythropoietin in kidney transplantation: experimental facts and clinical proofs |
| Q37563986 | The pathogenesis and treatment of chronic allograft nephropathy |
| Q37524979 | The renin-angiotensin system: an old, newly discovered player in immunoregulation |
| Q45241918 | The safe introduction of angiotensin-converting enzyme inhibitor in renal allograft recipients |
| Q34751942 | The urine albumin-to-creatinine ratio: assessment of its performance in the renal transplant recipient population |
| Q41696181 | Time-varying maximal proteinuria correlates with adverse cardiovascular events and graft failure in kidney transplant recipients |
| Q36599022 | Transplantation: The role of RAAS blockade in kidney transplantation |
| Q40488379 | Unique Considerations When Managing Hypertension in the Transplant Patient |
Search more.